A Cigna Healthcare study found administering pegfilgrastim, an injection used to prevent infection in cancer patients, in a home setting increased patient outcomes compared to administration in a nonhome setting.
The study, published in the Journal of Clinical Pathways, analyzed data from nearly 13,500 patients who received chemotherapy between Sep. 1, 2020, and Aug. 31, 2022. Patients who underwent home redirection were 32 percent less likely to have incidences of neutropenia, fever, pneumonia and sepsis.
The odds of same-day pegfilgrastim administration were 43 percent lower in patients who underwent home redirection, according to the study.